US2009257986A1PendingUtilityA1

Epidermal and dermal equivalents

61
Assignee: DFB PHARMACEUTICALS INCPriority: Jul 20, 1999Filed: Jan 14, 2009Published: Oct 15, 2009
Est. expiryJul 20, 2019(expired)· nominal 20-yr term from priority
A61P 17/02C12N 5/063C12N 5/0627A61P 17/00C12N 2533/30A61L 27/60C12N 2510/04A61L 2430/18C12N 5/0628A61L 27/3804
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.

Claims

exact text as granted — not AI-modified
1 - 71 . (canceled) 
     
     
         72 . A method for treating a skin defect comprising applying an epidermal skin equivalent comprising keratinocyte precursor cells to the skin defect. 
     
     
         73 . A kit comprising an epidermal equivalent. 
     
     
         74 . A feeder cell system for producing keratinocyte precursor cells comprising a hair follicle, feeder cells, and a microporous insert membrane.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.